Please ensure Javascript is enabled for purposes of website accessibility

Why XBiotech Shares Are Tumbling 23.4% Today

By Todd Campbell - Updated Feb 13, 2020 at 12:04PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company's offer to buy back shares was overtendered, resulting in a prorated deal.

What happened

After XBiotech (XBIT -1.92%) announced that investors tendering shares as part of its buyback will be able to tender only 30.9 shares for every 100 desired, shares are down 23.4% as of 11:30 a.m. EST on Thursday.

So what

In December, XBiotech completed the sale of its only clinical-stage drug, bermekimab, to Johnson & Johnson (JNJ 1.75%) for $750 million.

A man biting his finger nail.

Image source: Getty Images.

After reviewing options on how to deploy its windfall, management decided to return $420 million to investors through a modified Dutch auction. The company agreed to pay no less than $30 per share for up to 14 million shares. Apparently investors liked the price because shareholders tendered 41,164,725 common shares for payment.

Since the number of shares tendered far exceeded the company's plan, the deal is being prorated, with a preliminary proration factor of 30.9%. This means the company is accepting 30.9 shares for every 100 shares tendered.

Proration allows every investor to receive something, but it also means that many investors hoping to unwind their entire position in XBiotech won't be able to through this buyback. Since the company had no other clinical-stage assets beyond bermekimab and thus is starting over from scratch, investors appear to be moving on to focus on other biotech stocks.

Now what

XBiotech still has plenty of money left over to restart research, and bermekimab's success could indicate that its approach can pay off again in the future. An anti-IL-1a antibody, bermekimab is under development for dermatology indications, including eczema. At the time of its purchase, J&J justified its decision, saying, "It [bermekimab] is the only antibody targeting IL-1a currently in clinical development and has the potential for superior efficacy and safety compared to the current standard of care." Clearly J&J thinks this drug could be a blockbuster someday. 

XBiotech can't pursue dermatology indications because of its J&J deal, but it can still develop drugs targeting other blockbuster indications, such as cancers and heart diseases. It can receive up to $600 million in future milestones if J&J expands bermekimab beyond dermatology, too.

Nevertheless, the potential for IL-1a targeting in other indications is unproven in clinical studies, so all but the most aggressive investors might want to sit on the sidelines on XBiotech until there's more insight into its R&D pipeline, including trial data. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

XBiotech Inc. Stock Quote
XBiotech Inc.
XBIT
$5.61 (-1.92%) $0.11
Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$176.98 (1.75%) $3.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
331%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/20/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.